A detailed history of Woodline Partners LP transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 276,904 shares of RLAY stock, worth $1.23 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
276,904
Previous 273,616 1.2%
Holding current value
$1.23 Million
Previous $1.78 Million 9.93%
% of portfolio
0.02%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.23 - $9.51 $20,484 - $31,268
3,288 Added 1.2%
276,904 $1.96 Million
Q2 2024

Aug 14, 2024

BUY
$5.9 - $8.02 $3,587 - $4,876
608 Added 0.22%
273,616 $1.78 Million
Q1 2024

May 15, 2024

BUY
$7.5 - $12.07 $172,560 - $277,706
23,008 Added 9.2%
273,008 $2.27 Million
Q2 2023

Aug 14, 2023

SELL
$9.99 - $18.27 $249,750 - $456,750
-25,000 Reduced 9.09%
250,000 $3.14 Million
Q1 2023

May 15, 2023

SELL
$15.0 - $22.76 $849,945 - $1.29 Million
-56,663 Reduced 17.08%
275,000 $4.53 Million
Q1 2022

May 16, 2022

BUY
$20.26 - $32.36 $1.54 Million - $2.46 Million
76,062 Added 29.76%
331,663 $9.93 Million
Q3 2021

Nov 15, 2021

SELL
$29.75 - $37.99 $980,441 - $1.25 Million
-32,956 Reduced 11.42%
255,601 $8.06 Million
Q2 2021

Aug 16, 2021

BUY
$27.5 - $38.19 $1.38 Million - $1.91 Million
50,117 Added 21.02%
288,557 $10.6 Million
Q1 2021

May 17, 2021

SELL
$32.52 - $61.53 $1.78 Million - $3.37 Million
-54,775 Reduced 18.68%
238,440 $8.24 Million
Q4 2020

Feb 16, 2021

SELL
$35.51 - $54.03 $2.08 Million - $3.17 Million
-58,608 Reduced 16.66%
293,215 $12.2 Million
Q3 2020

Nov 16, 2020

BUY
$32.81 - $45.1 $11.5 Million - $15.9 Million
351,823 New
351,823 $15 Million

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $535M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.